Showing results (541-550 of 2,338) with videos related to

Sort By:
Pageof 234
Clinical Lung Cancer|September 29, 2023
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver AlterationsMarta Brambilla, Teresa Beninato, Anna Piemontese, et al.
Clinical Lung Cancer|September 20, 2024
Stage-Specific Guideline Concordant Treatment Impacts on Survival in Nonsmall Cell Lung Cancer: A Novel Quality IndicatorSanuki Tissera, Baki Billah, Margaret Brand, et al.
Clinical Lung Cancer|February 26, 2026
Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR DatabaseDiana Kim, Sarah Blocker, Courtney C Cavalieri, et al.
Clinical Lung Cancer|October 18, 2024
FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R MutationQing Zhou, Jie Li, Shun-Dong Cang, et al.
Clinical Lung Cancer|May 10, 2026
A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)Noriko Mitome, Akira Hamada, Masashi Wakabayashi, et al.
Clinical Lung Cancer|May 11, 2026
Staging Modalities in Non-Small Cell Lung Cancer: Evidence-Based Guideline and Systematic Review by the Brazilian Group of Thoracic OncologyClarissa Baldotto, Eldsamira Mascarenhas, Ana Caroline Zimmer Gelatti, et al.
Clinical Lung Cancer|March 10, 2026
Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA StudyAnna Minchom, Byoung Chul Cho, Natasha B Leighl, et al.
Clinical Lung Cancer|July 14, 2023
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimensWilliam P Tompkins, Wei-Ting Hwang, Yu-Xiao Yang, et al.
Clinical Lung Cancer|August 5, 2023
Effect of Surgical Treatment for N2-Positive c-stage III Non-Small Cell Lung Carcinoma in the "PACIFIC" EraHiroyuki Adachi, Hiroyuki Ito, Tetsuya Isaka, et al.
Clinical Lung Cancer|July 23, 2023
Efficacy of Tyrosine Kinase Inhibitors in Primary Driver-Gene-Positive Combined Small-Cell Lung Cancer: A Retrospective StudyZheng Shi, Jingwen Wei, Wei Sun, et al.
Pageof 234